Questions about this study?
The HopeStage team will email you.
Active Not RecruitingNCT06741228
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
Researchers are comparing DT120 and placebo to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.
Medication studyAges 18–74United States
Understand this study
What is this study about?
Researchers are comparing DT120 and placebo to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.
Who could participate?
This study is for people with anxiety. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.
- Listed locations
- Gilbert, United States · Scottsdale, United States and 28 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 11, 2024
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 214
- Sponsor
- Definium Therapeutics US, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT06741228
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
Recruitment & locations
Not recruitingGilbert · Scottsdale · La Jolla
27 more locations
- San Francisco
- Santa Monica
- Denver
- Jacksonville
- Lauderhill
- Atlanta
- Decatur
- Savannah
- Chicago
- Boston
- Watertown
- Marlton
- New York
- The Bronx
- Cleveland
- Portland
- Moosic
- Philadelphia
- North Charleston
- Memphis
- Austin
- Dallas
- DeSoto
- Draper
- Orem
- Bennington
- Seattle
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing DT120 and placebo to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.
Who is behind this study?
The study sponsor is Definium Therapeutics US, Inc.
Does this study involve medication?
Yes. The study involves medication, including DT120.
Who can participate?
This study is for people with anxiety. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me